Hypera Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Hypera ha aumentado sus beneficios a una tasa media anual de 8%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 6.2% anual. Los ingresos han ido creciendo a una tasa media de 19.2% al año. La rentabilidad financiera de Hypera es de 12.8%, y sus márgenes netos son de 20.2%.

Información clave

8.0%

Tasa de crecimiento de los beneficios

7.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	12.4%
Tasa de crecimiento de los ingresos	19.2%
Rentabilidad financiera	12.8%
Margen neto	20.2%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%

Nov 21

Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing

Jun 20

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 16

Is Hypera (BVMF:HYPE3) A Risky Investment?

Feb 21

Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Jan 09

Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Dec 22

Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Nov 02

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Aug 27

Is Hypera (BVMF:HYPE3) A Risky Investment?

Jul 21

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Apr 15

With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

Feb 19

We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Jan 03

Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Oct 11

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31

Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Jul 19

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Jun 28

Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

Apr 14

I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Mar 25

Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Mar 04

Desglose de ingresos y gastos

Cómo gana y gasta dinero Hypera. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

BOVESPA:HYPE3 Ingresos, gastos y beneficios (BRL Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 24	7,778	1,570	2,548
30 Jun 24	8,001	1,693	2,507
31 Mar 24	8,043	1,704	2,511
31 Dec 23	7,915	1,649	2,521
30 Sep 23	8,189	1,772	2,531
30 Jun 23	8,086	1,741	2,492
31 Mar 23	7,751	1,694	2,375
31 Dec 22	7,546	1,705	2,299
30 Sep 22	7,051	1,640	2,121
30 Jun 22	6,648	1,636	2,017
31 Mar 22	6,260	1,660	1,955
31 Dec 21	5,937	1,618	1,895
30 Sep 21	5,446	1,577	1,872
30 Jun 21	4,902	1,462	1,756
31 Mar 21	4,445	1,382	1,626
31 Dec 20	4,089	1,322	1,564
30 Sep 20	3,883	1,243	1,538
30 Jun 20	3,803	1,165	1,605
31 Mar 20	3,726	1,106	1,635
31 Dec 19	3,295	1,189	1,611
30 Sep 19	3,294	1,252	1,558
30 Jun 19	3,233	1,225	1,508
31 Mar 19	3,180	1,164	1,469
31 Dec 18	3,724	1,135	1,481
30 Sep 18	3,789	1,288	1,508
30 Jun 18	3,716	1,251	1,477
31 Mar 18	3,613	1,200	1,430
31 Dec 17	3,500	1,111	1,410
30 Sep 17	3,291	819	1,397
30 Jun 17	3,226	795	1,380
31 Mar 17	3,216	743	1,394
31 Dec 16	3,228	647	1,372
30 Sep 16	3,202	557	1,360
30 Jun 16	3,129	432	1,339
31 Mar 16	3,046	349	1,323
31 Dec 15	2,957	345	1,307
30 Sep 15	1,589	263	774
30 Jun 15	2,039	326	944
31 Mar 15	2,447	360	1,095
31 Dec 14	2,768	338	1,245
30 Sep 14	4,498	400	1,913
30 Jun 14	4,423	357	1,863
31 Mar 14	4,359	249	1,851
31 Dec 13	4,259	259	1,804

Ingresos de calidad: HYPE3 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(20.2%) de HYPE3 son inferiores a los del año pasado (21.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de HYPE3 han crecido un 8% al año en los últimos 5 años.

Acelerando crecimiento: HYPE3 ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: HYPE3 tuvo un crecimiento negativo de los beneficios (-11.4%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (8.8%).

Hypera Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Second quarter 2024 earnings: EPS exceeds analyst expectations

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

Hypera S.A. to Report Q3, 2024 Results on Nov 06, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Recent updates

More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Price target decreased by 8.4% to R$33.76

Consensus EPS estimates fall by 11%

Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects

Second quarter 2024 earnings: EPS exceeds analyst expectations

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Now 27% undervalued after recent price drop

Now 22% undervalued after recent price drop

Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing

Now 23% undervalued after recent price drop

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Hypera S.A., Annual General Meeting, Apr 23, 2024

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Hypera (BVMF:HYPE3) A Risky Investment?

Hypera S.A. to Report Q3, 2024 Results on Nov 06, 2024

Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Third quarter 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued after recent price drop

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

New major risk - Financial position

Second quarter 2023 earnings released: EPS: R$0.79 (vs R$0.72 in 2Q 2022)

Is Hypera (BVMF:HYPE3) A Risky Investment?

First quarter 2023 earnings released

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

Full year 2022 earnings released: EPS: R$2.69 (vs R$2.56 in FY 2021)

Hypera S.A. to Report Q4, 2022 Results on Feb 16, 2023

We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Less than half of directors are independent

Third quarter 2022 earnings released

Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Hypera Reportedly in Merger Talks with Grupo NC

Hypera S.A. to Report Q3, 2022 Results on Oct 28, 2022

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

First quarter 2022 earnings: Revenues in line with analyst expectations

Less than half of directors are independent

Hypera S.A. to Report Q1, 2022 Results on Apr 28, 2022

Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

Hypera S.A., Annual General Meeting, Apr 26, 2022

I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Full year 2021 earnings: EPS exceeds analyst expectations

Hypera S.A. to Report Fiscal Year 2021 Results on Feb 24, 2022

Hypera S.A.(BOVESPA:HYPE3) dropped from Brazil Valor BM&FBOVESPA Index

Third quarter 2021 earnings released: EPS R$0.73 (vs R$0.56 in 3Q 2020)

Second quarter 2021 earnings released

First quarter 2021 earnings released: EPS R$0.48 (vs R$0.39 in 1Q 2020)

New 90-day low: R$30.52

Full year 2020 earnings released

Revenue and earnings beat expectations

Hypera S.A. to Report Q4, 2020 Results on Feb 26, 2021

New 90-day high: R$35.31

New 90-day high: R$32.34

Market bids up stock over the past week

New 90-day low: R$28.80

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings beat expectations

New 90-day low: R$30.22

Hypera S.A. (BOVESPA:HYPE3) completed the acquisition of Boehringer Ingelheim Buscopan brand and other assets from Boehringer Ingelheim International Gmbh, Boehringer Ingelheim do Brasil Química e Farmacêutica Ltda. and Boehringer Ingelheim Pharma GmbH & Co. KG.

New 90-day low - R$31.65